PMOS and delayed diagnosis: why the renaming of PCOS matters
The recent decision to rename Polycystic Ovary Syndrome as Polyendocrine Metabolic Ovarian Syndrome reflects more than a change in terminology. For many, it represents growing recognition that the condition has historically been misunderstood, oversimplified and, in some cases, inadequately diagnosed or managed.
Why the name has changed
The renaming follows a global review involving clinicians, researchers and patient groups over a 14 year period, amid concerns that the term “polycystic ovary syndrome” did not accurately reflect the nature of the condition.
Despite the name, many patients do not have ovarian cysts. Equally, the condition often extends far beyond reproductive symptoms, with wider hormonal, metabolic and long term health implications.
The new term, Polyendocrine Metabolic Ovarian Syndrome, is intended to better reflect the complexity of the condition and its potential impact across multiple body systems.
A condition which can present in very different ways
PMOS can affect individuals differently and symptoms may develop gradually over time.
These can include:
- Irregular or absent periods
- Fertility difficulties
- Weight gain or insulin resistance
- Acne or excess hair growth
- Hair thinning
- Fatigue and mental health impacts
For some, symptoms may initially appear unrelated or be attributed to other causes. This can make diagnosis more complex, particularly where the focus remains on individual symptoms rather than the wider clinical picture.
Recent commentary surrounding the renaming has highlighted concerns that the previous terminology may, in some cases, have contributed to delayed diagnosis or a narrower understanding of the condition.
The importance of timely diagnosis and appropriate management
Early diagnosis can be important, not only in helping individuals understand and manage symptoms, but also in identifying potential longer term health risks.
PMOS has been linked to increased risks of conditions including type 2 diabetes, cardiovascular disease and endometrial cancer, alongside fertility related issues.
Appropriate medical management will vary depending on individual circumstances, but timely investigation, clear communication and ongoing monitoring can play an important role in supporting patients and reducing longer term complications.
Why awareness matters
The renaming of PCOS to PMOS is likely to increase public awareness and encourage broader understanding of the condition.
Importantly, it also reflects wider discussion around women’s health and the importance of ensuring that symptoms are properly investigated and not dismissed or minimised.
While changing terminology alone will not resolve the challenges faced by patients, there is hope that greater awareness may contribute to earlier recognition, improved understanding and more consistent care moving forward.
Get in touch
If you have concerns regarding delays in diagnosis, treatment, or medical care, please contact our Medical Negligence team by email at medneg@attwaters.co.uk or by telephone on 0330 221 8855.
